Key result
The hypertrophic cardiomyopathy-causing cTnT-160E mutation decreased linker flexibility and moved it closer to the tropomyosin C terminus, altering weak actomyosin interactions.
Why the study?
No high-resolution structure exists for the cTnT linker region, limiting the understanding of its role in myofilament activation and the molecular mechanism of the hypertrophic cardiomyopathy-causing 160E mutation.
The hypertrophic cardiomyopathy-causing cTnT-160E mutation alters the position and flexibility of the troponin T linker region, providing a biophysical mechanism for the observed contractile dysfunction.
Hypothesis-generating for troponin linker-targeted HCM therapies; leaves open clinical translation from animal models.
Mutations in the cardiac thin filament (TF) have highly variable effects on the regulatory function of the cardiac sarcomere. Understanding the molecular-level dysfunction elicited by TF mutations is crucial to elucidate cardiac disease mechanisms. The hypertrophic cardiomyopathy-causing cardiac troponin T (cTnT) mutation 160Glu (160E) is located in a putative "hinge" adjacent to an unstructured linker connecting domains TNT1 and TNT2. Currently, no high-resolution structure exists for this region, limiting significantly our ability to understand its role in myofilament activation and the molecular mechanism of mutation-induced dysfunction. Previous regulated in vitro motility data have indicated mutation-induced impairment of weak actomyosin interactions. We hypothesized that cTnT-160E repositions the flexible linker, altering weak actomyosin electrostatic binding and acting as a biophysical trigger for impaired contractility and the observed remodeling. Using time-resolved FRET and an all-atom TF model, here we first defined the WT structure of the cTnT-linker region and then identified 160E mutation-induced positional changes. Our results suggest that the WT linker runs alongside the C terminus of tropomyosin. The 160E-induced structural changes moved the linker closer to the tropomyosin C terminus, an effect that was more pronounced in the presence of myosin subfragment (S1) heads, supporting previous findings. Our in silico model fully supported this result, indicating a mutation-induced decrease in linker flexibility. Our findings provide a framework for understanding basic pathogenic mechanisms that drive severe clinical hypertrophic cardiomyopathy phenotypes and for identifying structural targets for intervention that can be tested in silico and in vitro.
No takes yet. Share an insight, caveat, or question.
Abdullah et al. (2019) studied Hypertrophic cardiomyopathy. cTnT mutation 160Glu (160E) vs. Wild-type cTnT was evaluated on Structural changes in the cTnT-linker region. The hypertrophic cardiomyopathy-causing cTnT-160E mutation decreased linker flexibility and moved it closer to the tropomyosin C terminus, altering weak actomyosin interactions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: